Shots:

• The P-III AURORA 1 study involves assessing the efficacy and safety of Lupkynis (23.7mg- bid) + MMF and low-dose corticosteroids vs MMF and low-dose corticosteroids alone in 357 adults with SLE and LN
• The trial met its 1EP and 2EPs i.e. complete renal response rates (41% vs 23%) @52wks. and 50% reduction from baseline in UPCR @24 & 52wks. and time to UPCR <0.5 mg/mg respectively. The therapy was well tolerated with no new safety signals
• Lupkynis is the 1st FDA-approved oral therapy for LN. The company will share the longer-term safety and efficacy data from the ongoing AURORA 2 continuation study in the coming months

  Ref: BUSINESS WIRE | Image: Crunchbase